- Home
- GILD vs SAN Comparison
GILD vs SAN Comparison
Compare GILD & SAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- SAN
- Stock Information
- Founded
- GILD 1987
- SAN 1857
- Country
- GILD United States
- SAN Spain
- Employees
- GILD N/A
- SAN N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- SAN Commercial Banks
- Sector
- GILD Health Care
- SAN Finance
- Exchange
- GILD Nasdaq
- SAN Nasdaq
- Market Cap
- GILD 105.5B
- SAN 73.2B
- IPO Year
- GILD 1992
- SAN 1987
- Fundamental
- Price
- GILD $87.36
- SAN $5.00
- Analyst Decision
- GILD Buy
- SAN Buy
- Analyst Count
- GILD 19
- SAN 1
- Target Price
- GILD $86.44
- SAN N/A
- AVG Volume (30 Days)
- GILD 6.2M
- SAN 2.3M
- Earning Date
- GILD 11-06-2024
- SAN 10-29-2024
- Dividend Yield
- GILD 3.53%
- SAN 4.27%
- EPS Growth
- GILD N/A
- SAN 23.74
- EPS
- GILD 0.84
- SAN 0.76
- Revenue
- GILD $27,805,000,000.00
- SAN $50,618,236,361.00
- Revenue This Year
- GILD $4.23
- SAN N/A
- Revenue Next Year
- GILD $0.87
- SAN $1.19
- P/E Ratio
- GILD $104.04
- SAN $6.35
- Revenue Growth
- GILD 1.54
- SAN 10.08
- 52 Week Low
- GILD $62.07
- SAN $3.52
- 52 Week High
- GILD $87.87
- SAN $5.27
- Technical
- Relative Strength Index (RSI)
- GILD 72.06
- SAN 52.34
- Support Level
- GILD $84.17
- SAN $4.93
- Resistance Level
- GILD $86.85
- SAN $5.08
- Average True Range (ATR)
- GILD 1.27
- SAN 0.07
- MACD
- GILD 0.00
- SAN -0.01
- Stochastic Oscillator
- GILD 94.19
- SAN 61.43
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
About SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.